

Philippe Auclair, **Senior Director - Abbott GSR**

Chair of the Medtech Europe PMS group, FRAPS







IMDRF codes- successes





- The web browser for IMDRF AE terms ensures user-friendly searching and hence better and more adequate use of terms by reporters/regulators.
- Annex A: Medical Device Problem
- Annex B: Cause Investigation Type of Investigation
- Annex C: Cause Investigation Investigation Findings
- Annex D: Cause Investigation Investigation Conclusion
- Annex E: Health Effects Clinical Signs and Symptoms or Conditions
- Annex F: Health Effects Health Impact
- Annex G: Medical Device Component














IMDRF codes- successes

- IMDRF Guidance Document: IMDRF terminologies for categorized Adverse Event Reporting(AER): terms, terminology structure and codes IMDRF/AE WG/N43FINAL:2020
- Video training available https://www.imdrf.org/imdrf-trainings









IMDRF codes- successes



• US FDA / EU 27 member states / Iceland. Liechtenstein. Norway. Switzerland/ United Kingdom.....

Benefits

- More efficient use of regulator and industry resources
- More efficient use of taxpayer funds
- Spread compliance costs over more markets
- Develop and promulgate regulatory best practices
- Pooling of expertise
- Regulatory capacity-building













What is next?

 In the end an "event" with device is globally the same, so why is reporting and relevant information are so different around the world?

Some potential improvements:

- Report What how?
- serious incident reporting- greater harmonization between forms/required formats (XML scheme?)
- Provide information globally -Establish a database to pool and analyze trends
- Limit country specific requirements and rely on available data across countries







Country requirements



- Enable pooling results- and avoid language translation
- Give a larger view instead of a macro country limited data
- Can establish an early warning system based on large data pool
- Use of Real World Data
- Enable for early detection signals

Examples-

- Rely on cross country data as more efficient than national practices e.g routine sample testing in lieu of comprehensive vigilance reporting
- Use of existing documents. EU PSUR adoption (Health Canada guidance), Serbia, Tanzania...













GMTA's message

"The future of medical products regulation is in convergence/harmonization, collaboration, and networking based on reliance and trust."









United States of America

2024

